COVID-19 Support


Gemini Bio Wins Federal Contract to Support COVID-19 Testing

* Will be increasing domestic production of reagents from its California facility, as well as its manufacturing footprint​

WEST SACRAMENTO, CA, June 11, 2020 – Gemini Bioproducts, LLC (“Gemini Bio”), a leading supplier of cell culture solutions and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), today announced the receipt of a federal government contract award to supply critical products in support of the high demand for COVID-19 testing.